The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.

A new ERAI report touches upon the Germany’s imports from China and prospects of the modal shift to railways. Over the past five years, China has been the main trading partner of Germany.